Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

GALIG Gene Expression in Parkinson's Disease (GALIGPARK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02923297
Recruitment Status : Completed
First Posted : October 4, 2016
Last Update Posted : March 28, 2017
Sponsor:
Collaborator:
Centre de Biophysique Moléculaire Orléans
Information provided by (Responsible Party):
Centre Hospitalier Régional d'Orléans

Brief Summary:
Parkinson's disease (PD) is the most frequent neurodegenerative disorder after Alzheimer's disease. It is characterized by motor symptoms (rigidity, tremor, slowness of movements), and non-motor symptoms (neuropsychological, psychiatric, pain ...). Neuronal death initiates in the brainstem and extends progressively through the entire cortex. The processes leading to cell death are poorly understood. Pathological cells exhibit abnormal deposits, called Lewy bodies, which contain numerous proteins. A major constituent of these protein deposits is alpha-synuclein. It has recently been demonstrated, in the Laboratory of Molecular Biophysics of the CNRS (Scientific Research National Center) in Orleans, that α-synuclein interacts with Cytogaligin, a protein produced by the proapoptotic GALIG gene. Cytogaligin could thus be a factor regulating α-synuclein activity or aggregation. It is postulated that the level of expression of the GALIG gene is different in Parkinson's disease patients compared with control subjects.

Condition or disease Intervention/treatment Phase
Parkinson Disease Other: Blood sampling Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: GALIG Gene Expression in Parkinson's Disease
Actual Study Start Date : April 2015
Actual Primary Completion Date : June 30, 2015
Actual Study Completion Date : June 30, 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Parkinson's disease patients
blood sampling
Other: Blood sampling
blood sampling for determine and compare the expression patterns of GALIG gene




Primary Outcome Measures :
  1. RNA (ribonucleic acid) assay of GALIG gene [ Time Frame: Day 0 ]
    Only one assessment in the study

  2. RNA (ribonucleic acid) assay of SNCA genes [ Time Frame: Day 0 ]
    Only one assessment in the study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with Parkinson's Disease according to the criteria of the UKPDBB (UK Parkinson's disease brain bank).

Exclusion Criteria:

  • Insane patient arriving without a third party.
  • Patient with Parkinson's disease arising from another etiology.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02923297


Locations
Layout table for location information
France
CHR d'ORLEANS
Orleans, France, 45067
Sponsors and Collaborators
Centre Hospitalier Régional d'Orléans
Centre de Biophysique Moléculaire Orléans
Investigators
Layout table for investigator information
Principal Investigator: Canan OZSANCAK, Ph CHR d'ORLEANS

Publications:
Layout table for additonal information
Responsible Party: Centre Hospitalier Régional d'Orléans
ClinicalTrials.gov Identifier: NCT02923297    
Other Study ID Numbers: CHRO-2014-05
First Posted: October 4, 2016    Key Record Dates
Last Update Posted: March 28, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Centre Hospitalier Régional d'Orléans:
parkinson
alpha-synuclein
GALIG
quantitative PCR (polymerase chain reaction)
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases